Article Versions Notes

Grambozov B, Zamani-Siahkali N, Stana M, Beheshti M, Ruznic E, Iskakova Z, Karner J, Zellinger B, Gerum S, Roeder F, et al. Delta Changes in [¹⁸F]FDG PET/CT Parameters Can Prognosticate Clinical Outcomes in Recurrent NSCLC Patients Who Have Undergone Reirradiation–Chemoimmunotherapy. Biomedicines. 2025; 13(8):1866. https://doi.org/10.3390/biomedicines13081866

Grambozov, Brane, Nazanin Zamani-Siahkali, Markus Stana, Mohsen Beheshti, Elvis Ruznic, Zarina Iskakova, Josef Karner, Barbara Zellinger, Sabine Gerum, Falk Roeder, and et al. 2025. "Delta Changes in [¹⁸F]FDG PET/CT Parameters Can Prognosticate Clinical Outcomes in Recurrent NSCLC Patients Who Have Undergone Reirradiation–Chemoimmunotherapy" Biomedicines 13, no. 8: 1866. https://doi.org/10.3390/biomedicines13081866

Grambozov, B., Zamani-Siahkali, N., Stana, M., Beheshti, M., Ruznic, E., Iskakova, Z., Karner, J., Zellinger, B., Gerum, S., Roeder, F., Pirich, C., & Zehentmayr, F. (2025). Delta Changes in [¹⁸F]FDG PET/CT Parameters Can Prognosticate Clinical Outcomes in Recurrent NSCLC Patients Who Have Undergone Reirradiation–Chemoimmunotherapy. Biomedicines, 13(8), 1866. https://doi.org/10.3390/biomedicines13081866